Akeso's Ivonescimab Plus Chemotherapy Cuts Death Risk 25% Versus Durvalumab Regimen in Biliary Tract Cancer Trial

• Akeso announced Oct. 26, 2026, that ivonescimab with chemotherapy improved overall survival versus durvalumab with chemotherapy in first-line advanced biliary tract cancer.
• Median overall survival reached 14.9 months versus 12.1 months; the risk of death fell 25% (P=0.0031).
• Median progression-free survival was 8.4 months versus 5.8 months; response rates reached 53.8% versus 32.5%.
• The Phase III HARMONi-GI1 trial enrolled 682 participants; no new safety signals emerged.
• The ivonescimab combination has been proposed for priority review by China's National Medical Products Administration for first-line biliary tract cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261026-12382417), on October 25, 2026, and is solely responsible for the information contained therein.